These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15688284)

  • 41. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
    Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J
    Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
    Jones T
    Curr Opin Mol Ther; 2004 Aug; 6(4):443-50. PubMed ID: 15468603
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris.
    Guzmán MG; Rodríguez R; Rodríguez R; Hermida L; Alvarez M; Lazo L; Muné M; Rosario D; Valdés K; Vázquez S; Martinez R; Serrano T; Paez J; Espinosa R; Pumariega T; Guillén G
    Am J Trop Med Hyg; 2003 Aug; 69(2):129-34. PubMed ID: 13677367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
    Dayan GH; Thakur M; Boaz M; Johnson C
    Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.
    Durbin AP; Kirkpatrick BD; Pierce KK; Elwood D; Larsson CJ; Lindow JC; Tibery C; Sabundayo BP; Shaffer D; Talaat KR; Hynes NA; Wanionek K; Carmolli MP; Luke CJ; Murphy BR; Subbarao K; Whitehead SS
    J Infect Dis; 2013 Mar; 207(6):957-65. PubMed ID: 23329850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
    Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
    J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
    Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
    Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
    Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans.
    Pittman PR; McClain D; Quinn X; Coonan KM; Mangiafico J; Makuch RS; Morrill J; Peters CJ
    Vaccine; 2016 Jan; 34(4):424-429. PubMed ID: 26718688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chokejindachai W; Jagsudee A; Saluzzo JF; Bhamarapravati N
    Am J Trop Med Hyg; 2002 Mar; 66(3):264-72. PubMed ID: 12139219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis.
    Pripuzova NS; Tereshkina NV; Gmyl LV; Dzhivanyan TI; Rumyantsev AA; Romanova LIu; Mustafina AN; Lashkevich VA; Karganova GG
    J Med Virol; 2009 Oct; 81(10):1777-85. PubMed ID: 19697399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
    Edelman R; Wasserman SS; Bodison SA; Putnak RJ; Eckels KH; Tang D; Kanesa-Thasan N; Vaughn DW; Innis BL; Sun W
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):48-60. PubMed ID: 14740955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted mutagenesis as a rational approach to dengue virus vaccine development.
    Blaney JE; Durbin AP; Murphy BR; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():145-58. PubMed ID: 19802584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine.
    Eckels KH; Kliks SC; Dubois DR; Wahl LM; Bancroft WH
    J Immunol; 1985 Dec; 135(6):4201-3. PubMed ID: 4067313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.
    Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA
    Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.